biostudies-literatureAmbros IMCancer Research UKNCI NIH HHS3685-3697https://www.ebi.ac.uk/biostudies/studies/S-EPMC7605396biostudies-literatureUnknown38(31)<h4>Purpose</h4>For localized, resectable neuroblastoma without <i>MYCN</i> amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome.<h4>Patients and methods</h4>Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group. Genomic data were analyzed using multi- and pangenomic techniques and fluorescence in-situ hybridization in 2 age groups (cutoff age, 18 months) and were quality controlled by the International Society of Pediatric Oncology European Neuroblastoma (SIOPEN) Biology Group.<h4>Results</h4>Patients with stage 1 tumors had an excellent Journal of clinical oncology : official journal of the American Society of Clinical OncologyAge Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.PMC760539623804U10 CA180886U10 CA180899Bown NCouturier JVan Roy NSchleiermacher GBeiske KKogner PValent ADefferrari RCastel VMazzocco KDe Bernardi BTweddle DABerbegall APLunec JMarques BCombaret VVillamon EMartinsson TMosseri VBenard JLadenstein RValteau-Couanet DMonclair TFNoguera RGlogova EHolmes KCohn SGross NJanousek DPearson ADJAmbros PFMichon JHogarty MDPark JRJeison MPotschger UAttiyeh EFBeck-Popovic MTonini GPAmbros IMCaron HPribill IDelattre OfalseAge Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.<h4>Purpose</h4>For localized, resectable neuroblastoma without <i>MYCN</i> amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome.<h4>Patients and methods</h4>Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group. Genomic data were analyzed using multi- and pangenomic techniques and fluorescence in-situ hybridization in 2 age groups (cutoff age, 18 months) and were quality controlled by the International Society of Pediatric Oncology European Neuroblastoma (SIOPEN) Biology Group.<h4>Results</h4>Patients with stage 1 tumors had an excellent 2020-01-01T00:00:00Z2020 Nov2025-05-29T19:01:14.203Z2022-02-11T12:21:15.342ZS-EPMC76053963290314010.1200/JCO.18.02132